Drug Reaction To Ursodeoxycholic Acid: Lichenoid Drug Eruption In An Infant Using Ursodeoxycholic Acid For Neonatal Hepatitis

Büyükgebiz, Benal; Arslan, Nur; Öztürk, Yeşim; Soyal, Cüneyt; Lebe, Banu

doi:10.1097/00005176-200209000-00030

Cited by 15 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, vaccines have been reported to cause LDE in a total of 8 (2.5%) cases (hepatitis A/B, influenza, herpes zoster, human papillomavirus) 115–119 Four cases (1.24%) of Capecitabine‐induced LDE were reported 120–123 . Two cases (0.62%) for each of the following drugs were identified: Thioridazine, leflunomide, ibuprofen, sildenafil and ursodeoxycholic acid 124–133 . Single cases of a large number of additional drugs were identified as listed in Table S1 33,77,86,134–169 …”

Section: Resultsmentioning

confidence: 99%

“…[120][121][122][123] Two cases (0.62%) for each of the following drugs were identified: Thioridazine, leflunomide, ibuprofen, sildenafil and ursodeoxycholic acid. [124][125][126][127][128][129][130][131][132][133] Single cases of a large number of additional drugs were identified as listed in Table S1. 33,77,86, T A B L E 1 Demographics of LDE cases analysed (n = 323).…”

Section: Culprit Medicationsmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications

Maul

Guillet

Oschmann

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

Cutaneous lichenoid drug eruptions (LDE) are adverse drug reactions (ADR) characterized by symmetric, erythematous, violaceous papules reminiscent but rarely fully characteristic of lichen planus (LP). We aimed to analyse the literature describing cases of LDE within the last 20 years to provide additional insight into culprit drugs, typical latency to onset of the eruption, the spectrum of clinical presentations, severity and management. A literature search was conducted in MEDLINE between January 2000 and 27 January 2021. The keywords ‘lichenoid drug rash’ and ‘lichenoid drug eruption’ were used. Cases were included if LDE diagnosis was made, and culprit drugs were identified. A total of 323 cases with LDE were identified from 163 published case reports and studies. The mean patient age was 58.5 years (1 month to 92 years), and 135 patients (41.8%) were female. Checkpoint inhibitors (CKI) were the most frequently reported culprit drugs (136 cases; 42.1%), followed by tyrosine kinase inhibitors (TKI) (39 cases; 12.0%) and anti‐TNF‐α‐monoclonal antibodies (13 cases; 4.0%). The latency between initiation of the drug and manifestation was 15.7 weeks (range: 0.1–208 weeks). After discontinuing the culprit drug, the median time to resolution was 14.2 weeks (range: 0.71–416 weeks). One hundred thirty‐six patients (42.1%) were treated with topical, and 54 patients (16.7%) with systemic glucocorticoids. Overall, we conclude that, albeit rare, LDE is challenging to diagnose ADR induced by mostly CKI, TKI, and biologics. Treatment modalities resemble that of lichen planus, and the culprit drugs had to be discontinued in only 26%, which is low compared with other types of adverse drug reactions. This is probably due to the low risk of aggravation (e.g. toxic epidermal necrolysis) if the drug is continued and the benefit/risk ratio favouring the drug, as is often the case in cancer therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Culprit Medicationsmentioning

confidence: 99%

Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications

Maul

Guillet

Oschmann

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…A skin eruption initially attributed to UDCA was caused by allergy to a co‐ingredient, as shown by lymphocyte stimulating tests 90 . A lichenoid skin eruption was reported in an infant with neonatal hepatitis treated with UDCA, but the component of the UDCA preparation responsible for the skin reaction remains unclear 91 …”

mentioning

confidence: 99%

Ursodeoxycholic acid — adverse effects and drug interactions

Hempfling¹,

Dilger

Beuers³

2003

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Ursodeoxycholic acid is increasingly being used for the treatment of chronic cholestatic liver diseases. It appears to be generally well tolerated, but a systematic review on drug safety is lacking. Aim: As experimental data suggest a role of bile acids in the regulation of hepatic drug metabolism at both the transcriptional and post-transcriptional level, the literature was screened for adverse drug reactions and drug interactions related to ursodeoxycholic acid. Methods: A systematic review of the literature was performed using a refined search strategy to evaluate the adverse effects of ursodeoxycholic acid and its interactions with other drugs. Results: Ursodeoxycholic acid caused diarrhoea in a small proportion of patients. Rare skin reactions were

show abstract

“…Pediatric LDE is infrequent due to the relative uncommon use of systemic medications in this age group. A review of the current literature revealed several cases of cutaneous LDE in children (28,29). However, reports of OLDE are extremely rare and may be related to lack of recognition or misdiagnosis as other clinical entities, including idiopathic LP.…”

Section: Discussionmentioning

confidence: 99%

Oral Lichenoid Drug Eruption: A Report of a Pediatric Case and Review of the Literature

Woo

Bonks

Borukhova

et al. 2009

Pediatric Dermatology

View full text Add to dashboard Cite

Lichenoid drug eruptions are seen most frequently on the skin and seldomly affect the mucosal surfaces. Oral involvement-known as oral lichenoid drug eruption-is more common in the adult population and has been associated with numerous medications. Pediatric-onset oral lichenoid drug eruption is an exceptionally rare finding with only isolated cases published in the literature. The nonspecific appearance and latent presentation of pediatric oral lichenoid drug eruption can cause confusion in diagnosis and treatment. We report a case of oral lichenoid drug eruption occurring in a 15-year-old and explore challenges in the clinical and histologic recognition of this condition.

show abstract

Drug Reaction To Ursodeoxycholic Acid: Lichenoid Drug Eruption In An Infant Using Ursodeoxycholic Acid For Neonatal Hepatitis

Cited by 15 publications

References 14 publications

Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications

Cutaneous lichenoid drug eruptions: A narrative review evaluating demographics, clinical features and culprit medications

Ursodeoxycholic acid — adverse effects and drug interactions

Oral Lichenoid Drug Eruption: A Report of a Pediatric Case and Review of the Literature

Contact Info

Product

Resources

About